in this episode... we dive into Hepatitis Delta Virus (HDV), a defective virus that causes the most severe form of viral hepatitis, requiring the presence of Hepatitis B surface antigen (HBsAg) to reproduce. Chronic HDV is a substantial global burden, affecting an estimated 48 to 60 million people worldwide, and leads to an accelerated disease course, with progression to cirrhosis typically taking 5 years and hepatocellular carcinoma (HCC) about 10 years. The International Agency for Research on Cancer (IARC) recently classified chronic HDV infection as a Group 1 carcinogen. Historically, the sole treatment was pegylated interferon-alpha (PegIFN-α), which had suboptimal efficacy and considerable adverse effects. However, the therapeutic landscape is shifting with the introduction of new agents, including the entry inhibitor bulevirtide (approved in Europe) and the farnesyl transferase inhibitor lonafarnib. Future strategies are focusing on powerful combination therapies—such as tobevibart and elebsiran—designed to achieve HBsAg clearance, which is considered essential for a durable functional cure.

In this episode, we define Sudden Sensorineural Hearing Loss (SSNHL) as a critical hearing emergency, typically involving a rapid loss of at least 30 dB across three consecutive frequencies within 72 hours. We discuss that while the cause is idiopathic in 71% to 90% of cases, successful management demands immediate diagnosis through audiometry, and MRI or ABR must be performed to rule out retrocochlear tumors like acoustic neuroma. Treatment is centred on corticosteroids, with evidence suggesting that intratympanic steroid injections may achieve a higher rate of complete hearing recovery compared to systemic steroids, making it especially useful for patients where systemic therapy is contraindicated, such as those with diabetes or hypertension. Additionally, hyperbaric oxygen therapy combined with steroids is recommended as an option for initial therapy within two weeks of onset.

in this episode, we explore Non-Immune Hydrops Fetalis (NIHF), a severe fetal condition defined by abnormal fluid accumulation in at least two fetal compartments. NIHF accounts for up to 90% of all hydrops cases and is linked to a wide spectrum of underlying causes, including cardiovascular disorders, chromosomal abnormalities, infections (like Parvovirus B19), and monogenic genetic disorders. Given the high mortality rate, identifying the specific etiology is crucial for effective management and determining prognosis. While many cases remain unexplained, a thorough diagnostic approach utilizing advanced tools like chromosomal microarray analysis (CMA) and Whole Exome Sequencing (WES) is recommended to identify the underlying genetic cause, which is essential for guiding treatment and counseling families. If a treatable cause is found, such as fetal anemia or arrhythmia, targeted interventions like intrauterine transfusions or medication can be implemented.

super short podcast summary: in this episode... we explore Triple X Syndrome (47,XXX), a genetic condition affecting about 1 in 1,000 female births due to the presence of an extra X chromosome. The syndrome is highly variable; symptoms are often subtle, mild, or absent, although features can include tall stature, speech and motor delays, and learning disabilities. Detection has increased due to the use of Non-Invasive Prenatal Testing (NIPT), but diagnostic testing is necessary to confirm a positive NIPT result. Importantly, most individuals with Triple X Syndrome have normal sexual development and fertility, and lead normal, healthy, and productive lives.

in this episode, we discuss renal dysplasia (a type of congenital anomaly of the kidney and urinary tract - CAKUT), which is the most frequent cause of chronic kidney disease (CKD) and end-stage renal failure (ESRF) in children. This condition is defined by abnormal kidney development, leading to the presence of disorganized histological architecture and primitive embryological tissues. Diagnosis typically begins with prenatal ultrasonography, and genetic analysis often reveals complex causes, including chromosomal abnormalities (like the 17q12 deletion) or monogenic variants in genes like PAX2 and SALL1. Management is focused on lifelong monitoring, especially in bilateral cases, requiring at least twice-yearly assessment of blood pressure and proteinuria to slow CKD progression. Furthermore, advanced research is using kidney organoids derived from stem cells to model genetic diseases like CAKUT and screen new drugs, while pharmaceutical trials are investigating novel agents such as Runcaciguat and Cotadutide for CKD treatment.

In this episode, we define Systemic Lupus Erythematosus (SLE) as a severe, chronic autoimmune disease characterized by a global loss of self-tolerance and pathogenic autoantibody production, affecting organs such as the heart, brain, and kidneys. Pathogenesis involves innate immune dysregulation, prominently featuring a Type I Interferon signature, which is amplified by mechanisms like the release of self-DNA complexes via netting neutrophils.

For classification, the EULAR/ACR 2019 criteria are considered optimal for classifying adult-onset SLE, while the SLICC 2012 criteria are best for childhood-onset SLE. Critically, monitoring is key: disease flares are often signaled by rising anti-dsDNA antibodies coupled with a characteristic drop in C3 and C4 complement factors.

Treatment focuses on minimizing glucocorticoid use and achieving remission. Hydroxychloroquine is the foundational therapy recommended for all patients, as it helps prevent flares, organ damage, and thrombosis. We emphasize that controlling disease activity is vital, as accelerated atherosclerosis is the leading cause of late mortality in SLE patients.

in this episode, we explored Asherman syndrome (IUA), a condition where scar tissue forms inside the uterus, typically following trauma like dilation and curettage (D&C) after pregnancy, leading to infertility, recurrent pregnancy loss, and menstrual abnormalities. Diagnosis relies on hysteroscopy as the gold standard. We examined the traditional American Fertility Society (AFS) system and introduced the Loddo Scoring System, a novel classification that integrates ultrasonographic endometrial thickness (assigning a high score for ≤5 mm) and reproductive history to provide a precise prognosis. The standard treatment, Hysteroscopic Adhesiolysis (HA), aims to restore the uterine anatomy. However, HA alone often fails to fully repair the functional damage, resulting in reduced conception rates for severe cases. A major obstetric complication following treatment is a critical, quantified risk (reported between 2.5% and 2.6%) of Placenta Accreta Spectrum (PAS) disorders in subsequent pregnancies. Finally, we looked toward regenerative medicine, noting that therapies like stem cell therapy are being investigated to achieve true functional regeneration of the basal endometrium, moving beyond the limitations of surgery alone.

ORPHA:137686

Classification level: Disorder

Source: PubMed ID 37490750 30936754 37735465

Prevalence: 1-5 / 10 000

Inheritance: Not applicable

Age of onset: Adult

ICD-10: N85.6 

ICD-11: GA16.2

UMLS: C0156372 

GARD: 5853

MedDRA: 10053868

in this episode, we dive into preeclampsia (PE), a multisystem hypertensive disorder of pregnancy, and the modern diagnostic criteria that define it by new-onset hypertension (SBP ≥140 or DBP ≥90 mm Hg) and signs of multi-organ damage, often irrespective of proteinuria. Preeclampsia's pathogenesis is rooted in a two-stage model, starting with abnormal placentation (Stage 1), which leads to a systemic endothelial dysfunction (Stage 2) caused by the release of anti-angiogenic factors like soluble fms-like tyrosine kinase 1 (sFlt-1). We cover acute management, emphasizing the critical need to treat sustained severe hypertension (SBP ≥160 or ≥DBP 110 mm Hg) within 60 minutes using first-line agents such as immediate-release oral nifedipine, IV labetalol, or IV hydralazine. For prevention, low-dose aspirin (LDA) (81 mg/day) is the primary recommendation for high-risk patients, typically initiated after 12 weeks of gestation, with research ongoing into promising novel agents like pravastatin (a statin). Finally, we discuss the severe long-term impact of PE, noting that it significantly increases the mother's lifetime risk for chronic hypertension and cardiovascular disease and is linked to elevated neurodevelopmental risks like Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD) in the offspring.

ORPHA:275555

Classification level: Disorder

Source: PubMed ID 34033373 35177220

Prevalence: 1-5 / 10 000

Inheritance: Not applicable

Age of onset: Adult

ICD-10: O14.2 , O14.9 , O14.0 , O14.1 

ICD-11: JA24.0 JA24.1 JA24

OMIM: 189800 609402609403 609404 614595

UMLS: C0032914 

MeSH: D011225 

MedDRA: 10036485

in this episode... we detail Necrotizing Enterocolitis (NEC), a devastating inflammatory disease predominantly affecting premature infants, driven by gut dysbiosis and exaggerated Toll-like Receptor 4 (TLR4) signaling. We review current strategies like the use of human milk, which reduces risk, and probiotics, which lack standardized guidelines despite strong evidence of benefit. Finally, we highlight the urgent need for a standardized NEC definition and the development of new biomarkers (e.g., SAA, PCT, HMGB1) and targeted therapies (e.g., TLR4 antagonists) to improve early diagnosis and treatment outcomes.

ORPHA:391673

Classification level: Disorder

Source: PubMed ID 30020729 36714655

Prevalence: 1-5 / 10 000

Inheritance: Not applicable

Age of onset: Neonatal

ICD-10: P77 

ICD-11: KB88

UMLS: C0520459 

MeSH: D020345 

GARD: 9767

in this episode, we explore Chronic Lymphocytic Leukemia (CLL), the most common adult leukemia in the Western world, characterized by the progressive accumulation of malignant B lymphocytes. Diagnosis relies on flow cytometry, but because the disease is typically indolent, initial management is generally a "watch and wait" approach until symptoms appear, as early intervention does not improve overall survival. When treatment is needed, the current paradigm favors targeted agents—such as Bruton tyrosine kinase (BTK) inhibitors and Bcl-2 inhibitors (venetoclax)—over traditional chemoimmunotherapy.

ORPHA:67038

Classification level: Disorder

• B-CLL
• B-cell chronic lymphoid leukemia
• Small lymphocytic lymphoma
• CLL
• CLL/SLL
• Chronic lymphocytic leukemia

Source: PubMed ID 36446777 32229611 37899041

Prevalence: 1-5 / 10 000

Inheritance: Multigenic/multifactorial, Not applicable

Age of onset: Adult

ICD-10: C91.1 

ICD-11: 2A82.0

OMIM: 109543 151400609630 612557 612558612559

UMLS: C0023434 

MeSH: D015451 

GARD: 6104

MedDRA: 10008958